Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Lawrence Livermore National ... (WIB) and Las Positas College (LPC) recently established ... and hands-on training for veterans, officials recently announced. ... Las Positas is designed to help veterans ... technician careers, and establishes a pipeline of qualified ...
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... EUGENE, Ore. (July 21, 2014) The yield ... of Oregon have developed a low-energy, solution-based mineral substitution ... that could find use in electronics and alternative energy ... on the cover of the July 21 issue of ... most citations of research in the inorganic and nuclear ...
(Date:7/21/2014)... York , July 21, 2014 ... on Global & USA ... Trends, and Forecasts ResearchMoz presents this ... Biomaker Market   to 2018 (Identification, Technologies, Market Analysis, ... Trends, and Pipeline Analysis. GLOBAL & ...
Breaking Biology Technology:Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Carbyne morphs when stretched 2Carbyne morphs when stretched 3Oregon chemists eye improved thin films with metal substitution 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... Oncology Biomarkers, FREMONT, Calif., Feb. 6 ... high-value molecular diagnostics company, today announced,the renewal ... University,on the development of novel biomarkers that ... monitoring of prevalent cancers, including,ovarian, breast and ...
... BRL ) today announced that its subsidiary, Barr ... Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg after receiving ... The FDA approved the Company,s application on February ... the,earliest to expire of the patents listed with the ...
... 6 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the 10th Annual BIO,CEO & ... 12. Mr. Erck,s,presentation will begin at 2 p.m. Eastern ... Mr. Erck will give an update on corporate ...
Cached Biology Technology:Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:7/22/2014)... showed that mutations in prickle genes cause epilepsy, ... by repeated seizures over time. However, the mechanism ... A new University of Iowa study, published online ... National Academy of Sciences , reveals a novel ... have identified the basic cellular mechanism that goes ...
(Date:7/22/2014)... research in the Journal of Clinical ... signaling and dopamine transporter function are linked ... Parkinsonism and attention deficit hyperactivity disorder (ADHD). ... critical basis for further exploration of how ... contribute to brain disorders" said Michelle Sahai, ...
(Date:7/22/2014)... on July 14, 2014, by lightning from a weather system ... of four fires: Stokes Fire, Gold Hikes Fire, French Creek ... fires are now one larger fire. The fires are burning ... over 243,000 acres in size. The present fire situation ... Public and firefighter safety is the priority on the Carlton ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2The dopamine transporter 2The dopamine transporter 3
... from early hominid to dominant species, is the defining ... To chronicle this epic narrative an internationally renowned team, ... University, presents the Wiley-Blackwell Encyclopedia of Human Evolution, a ... history. Over two volumes and 5000 entries ...
... Boston, MA - Some 25 million people in the United ... diseases characterized by often debilitating pain in the joints. Now ... gel that could spell the future for treating these diseases ... the targeted release of medicine at an affected joint, and ...
... crustaceans called copepods rule the world, at least when ... numerous multi-cellular organisms in the seas, copepods are an ... webs. To understand and predict how copepods respond ... how many new copepods are born, but how many ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
Acetylcholinesterase (human brain, AChE)...
... 7500ce meets the demands of the routine ... performance from reliable, robust and simple to ... power in the most challenging sample matrices ... equally suited to the toughest analytical challenges ...
Biology Products: